• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24894 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     National Institute for Health and Care Excellence (NICE) VA ECMO for severe acute heart failure in adults. NICE interventional procedures guidance 807
2008     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against cervical cancer
1991     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against Haemophilus influenzae type b
2009     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against pandemic influenza A/H1N1 2009: target groups and prioritisation
2004     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against pertussis
2015     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against pertussis: aims and strategy
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) Vaccination contre la grippe dans le contexte particulier de la pandémie COVID-19 : intérêt et populations prioritaires
2003     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of children against hepatitis B
2013     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of infants against pneumococcal infections (3)
2011     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of young children against tuberculosis
2000     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination policies in case of an influenza pandemic
2010     NIHR Health Technology Assessment programme Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccine for herpes simplex
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccine for herpes zoster
2012     Belgian Health Care Knowledge Centre (KCE) Vaccine safety surveillance in Belgium : place and limits of a background rate approach
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for avian influenza
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for HIV
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for metastatic hormone-refractory prostate cancer
2015     NIHR Health Technology Assessment programme Vaccines for preventing influenza in healthy adults (A060)
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for prevention of human papillomavirus infection
2003     Quality Improvement Scotland (NHS QIS ) Vacuum assisted closure (VAC) for wound healing
2004     Medical Advisory Secretariat (MAS) Vacuum assisted closure therapy for wound care
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vacuum assisted wound closure therapy
2025     Scottish Health Technologies Group (SHTG) Vacuum bell device for people with pectus excavatum
2006     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) Vacuum-assisted breast biopsy
2003     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vacuum-assisted closure for the management of wounds: an accelerated systematic review
2000     ECRI Vacuum-assisted wound closure for chronic and acute wounds
2005     Technology Assessment Unit of the McGill University Health Centre (MUHC) Vacuum-assisted wound closure therapy (V.A.C (R))
2025     National Institute for Health and Care Excellence (NICE) Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease. NICE technology appraisal guidance 1035
2003     Agency for Healthcare Research and Quality (AHRQ) Vaginal birth after Cesarean (VBAC)
2010     Agency for Healthcare Research and Quality (AHRQ) Vaginal birth after cesarean: new insights
1993     Danish Institute for Health Services Research (DSI) Vaginal bleeding disorders. Consensus statement
2010     Adelaide Health Technology Assessment (AHTA) Vaginal brachytherapy for treatment of women with high-intermediate risk of endometrial cancer
2000     HAYES, Inc. Vaginal hormonal cytology for the diagnosis and management of menopause
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vaginal micronized progesterone capsules for the prevention of miscarriage and preterm birth: a review of the clinical evidence
2021     Ontario Health Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Vaginal preparation prior to cesarean delivery: clinical evidence
2023     National Institute for Health and Care Excellence (NICE) Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. NICE interventional procedures guidance 774
1997     Alberta Heritage Foundation for Medical Research (AHFMR) Vaginoplasty in male-female transsexuals and criteria for sex reassignment surgery
2015     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve blocking and gastric artery embolisation for obesity
2000     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vagus nerve stimulation (VNS) for treatment-resistant depression
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation for chronic major depressive episodes
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation for chronic major depressive episodes
2009     HAYES, Inc. Vagus nerve stimulation for depression
2005     HAYES, Inc. Vagus nerve stimulation for depression
2013     HAYES, Inc. Vagus nerve stimulation for depression
2009     HAYES, Inc. Vagus nerve stimulation for depression
2008     Adelaide Health Technology Assessment (AHTA) Vagus nerve stimulation for epilepsy
2009     HAYES, Inc. Vagus nerve stimulation for epilepsy
2008     Medical Services Advisory Committee (MSAC) Vagus nerve stimulation for epilepsy
2003     HAYES, Inc. Vagus nerve stimulation for epilepsy
2007     HAYES, Inc. Vagus nerve stimulation for epilepsy
2014     HAYES, Inc. Vagus nerve stimulation for epilepsy
1998     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2001     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Vagus Nerve Stimulation for refractory epilepsy
2001     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2004     National Institute for Health and Care Excellence (NICE) Vagus nerve stimulation for refractory epilepsy in children. NICE interventional procedures guidance 50
1998     ECRI Vagus nerve stimulation for the treatment of intractable epilepsy
2006     Blue Cross Blue Shield Association (BCBS) Vagus nerve stimulation for treatment-resistant depression
2005     Blue Cross Blue Shield Association (BCBS) Vagus nerve stimulation for treatment-resistant depression
1998     Wessex Institute for Health Research and Development (WIHRD) Vagus nerve stimulation in epilepsy
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2015     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2022     Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vagus nerve stimulator (VNS)
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Valdecoxib
2026     Swiss Federal Office of Public Health (FOPH) Valerian extracts for sleep disorders, anxiety or restlessness
2008     HAYES, Inc. Valerian for treatment of insomnia
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valganciclovir (Valcyte®) powder for oral solution
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valganciclovir (Valcyte®) tablets
2026     NIHR Health Technology Assessment programme Validating and updating the OHTS-EGPS model predicting 5-year glaucoma risk among patients with ocular hypertension using electronic medical records: a cohort study
2020     NIHR Health Technology Assessment programme Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis
2002     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Validation: dementia in elder people - primary research
2002     Centre for Clinical Effectiveness (CCE) Validity of the venous thromboembolism risk factor assessment model as described by Motykie et al (2000)
2020     Institute for Clinical and Economic Review (ICER) Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valsartan (Diovan®)
2023     Institute for Clinical and Economic Review (ICER) Value assessment framework
2014     University of York Value based commissioning of MSK Procedures: an appraisal of the evidence for the proposed policies
1994     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Value of echoendoscopy in gastrointestinal disease
2007     Haute Autorite de sante (HAS) Value of extra-cranial stereotactic radiotherapy
2006     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Value of intensified nursing
2007     Haute Autorite de sante (HAS) Value of intensity-modulated radiation therapy
1999     Hannover Medical School, Medizinische Hochschule Hannover (MHH) Value of intravascular ultrasound (IVUS) in diagnostic and therapeutic heart catherisation in patients with coronary heart disease - an economic health technology assessment
2007     Haute Autorite de sante (HAS) Value of mandibular advancement devices in cases of obstructive sleep apnea-syndrome
2005     Haute Autorite de sante (HAS) Value of measuring FSH and LH levels in women aged 45 or over
2007     Haute Autorite de sante (HAS) Value of mutation detection and of the activated protein C resistance assay in inherited thrombophilia
2006     Agency for Healthcare Research and Quality (AHRQ) Value of the periodic health evaluation
2011     Agency for Healthcare Research and Quality (AHRQ) Values of older adults related to primary and secondary prevention
2019     National Institute for Health and Care Excellence (NICE) Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction. NICE interventional procedures guidance 653
2025     National Institute for Health and Care Excellence (NICE) Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over. NICE technology appraisal guidance 1031
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin or metronidazole for treatment of clostridium difficile infection: clinical and economic analyses
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2015     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima, -6474, AZD-6474, ZD6474) for medullary thyroid cancer – locally advanced or metastatic
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer
2018     National Institute for Health and Care Excellence (NICE) Vandetanib for treating medullary thyroid cancer. NICE technology appraisal guidance 550
2025     National Institute for Health and Care Excellence (NICE) Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over. NICE technology appraisal guidance 1085
2009     Penn Medicine Center for Evidence-based Practice (CEP) Varenicline for smoking cessation